Explore › Condition › Overactive Bladder
Condition

Overactive Bladder

Also known as: Bladder instability Bladder muscle dysfunction - overactive Bladder muscle dysfunction - overactive (disorder) Bladder, Overactive Hyperactive bladder Hypertonic bladder Hypertonic bladder (disorder) Hypertonicity of bladder Instability of bladder Overactive Bladder Overactive Urinary Bladder Overactive bladder +5 more
3 findings 1 paper 3 related entities View in graph →

Related entities

interventions
OnabotulinumtoxinA 200 unit powder for solution for injection vial1
outcomes
Overactive Bladder1
studys
PMC53994191

Findings (27)

None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →
None
improvement

OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8

Effect: improvement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Size: mean difference, 8.1 on OAB-q SF symptom bother CI: 95% CI, 3.0 to 13.3
PMC5399419
Finding details → · Paper → · Graph →

Papers (1)